Latest news with #FlexTouch
Economic Times
an hour ago
- Health
- Economic Times
Novo Nordisk's Wegovy enters India: Can this weight loss jab beat Mounjaro? Price, who can use it & how it works
Novo Nordisk has launched Wegovy, a weight loss injection, in India, challenging Eli Lilly's Mounjaro. Available by June 2025, Wegovy contains semaglutide, mimicking a hormone to control blood sugar and reduce hunger. Priced from Rs 17,345 to Rs 26,015 monthly, it showed significant weight loss in trials. Tired of too many ads? Remove Ads India's obesity market is growing fast Tired of too many ads? Remove Ads How Wegovy Works Wegovy India Price List Dose Monthly Price (Rs) Price Per Dose (Rs) 0.25 mg Rs 17,345 Rs 4,366 0.5 mg Rs 17,345 Rs 4,366 1 mg Rs 17,345 Rs 4,366 1.75 mg Rs 24,280 Rs 6,070 2.4 mg Rs 26,015 Rs 6,503 Mounjaro Dose Monthly Price (Rs) 2.5 mg Rs 14,000 5 mg Rs 17,500 Almost like weight loss surgery, but with a catch Wegovy vs Mounjaro: What's the Difference? Feature Wegovy (Semaglutide) Mounjaro (Tirzepatide) How it works Mimics GLP-1 hormone Acts on GLP-1 and GIP hormones Effect Lowers appetite, slows digestion Improves insulin and reduces appetite Approved for Weight loss Diabetes (off-label for weight loss) How to use Weekly injection via Flexpen Weekly injection via vial Price range Rs 17,345–Rs 26,015 Rs 14,000–Rs 17,500 In a big step for India's weight loss drug market, Danish pharmaceutical company Novo Nordisk has officially launched Wegovy , its much-talked-about weight loss injection. The company is now competing directly with Eli Lilly's popular drug, Mounjaro Wegovy is a once-a-week injection that comes in a pen-like device called FlexTouch. It's easy to use and doesn't require vials or syringes. According to Managing Director of Novo Nordisk India, Vikrant Shrotriya, the drug will be available in pharmacies across India by the end of June 2025, The Times of India has one of the world's highest numbers of people struggling with weight. Around 254 million people have general obesity and over 351 million suffer from belly fat-related issues. With the anti-obesity medicine market jumping from Rs 133 crore in 2021 to Rs 576 crore today (as per PharmaTrac), Novo Nordisk sees a huge said, 'Obesity is a chronic illness and a growing problem in India. Wegovy is easy to use and will be priced specially for Indian patients.'Wegovy contains a compound called semaglutide , which mimics a natural hormone in the body. This hormone helps control blood sugar, reduce hunger, slow digestion, and make you feel full for longer. While similar drugs like Ozempic are meant for diabetes, Wegovy is approved for long-term weight comes in a FlexTouch device, allowing users to adjust their weekly dose easily. Each monthly pack includes four needles. The medicine works on brain areas that manage appetite and food to Dr V. Mohan, a well-known diabetologist, 'Semaglutide not only helps in weight loss but also improves heart and inflammation markers. It's a strong option for Indian patients dealing with both obesity and rising heart risks.'For comparison, Eli Lilly's Mounjaro is slightly cheaper:Wegovy has shown very strong results. In global studies, people lost up to 15% of their weight on average, and some even lost 20%. It also helped lower the risk of heart attacks and strokes and improved liver the results are mostly maintained only if the person continues using the drug. If stopped, weight gain can return. Doctors also warn that muscle loss may happen over time, so people need to be regularly from TOI
Time of India
2 hours ago
- Health
- Time of India
Novo Nordisk's Wegovy enters India: Can this weight loss jab beat Mounjaro? Price, who can use it & how it works
In a big step for India's weight loss drug market, Danish pharmaceutical company Novo Nordisk has officially launched Wegovy , its much-talked-about weight loss injection. The company is now competing directly with Eli Lilly's popular drug, Mounjaro . Wegovy is a once-a-week injection that comes in a pen-like device called FlexTouch. It's easy to use and doesn't require vials or syringes. According to Managing Director of Novo Nordisk India, Vikrant Shrotriya, the drug will be available in pharmacies across India by the end of June 2025, The Times of India reported. India's obesity market is growing fast India has one of the world's highest numbers of people struggling with weight. Around 254 million people have general obesity and over 351 million suffer from belly fat-related issues. With the anti-obesity medicine market jumping from Rs 133 crore in 2021 to Rs 576 crore today (as per PharmaTrac), Novo Nordisk sees a huge opportunity. Shrotriya said, 'Obesity is a chronic illness and a growing problem in India. Wegovy is easy to use and will be priced specially for Indian patients.' Live Events How Wegovy Works Wegovy contains a compound called semaglutide , which mimics a natural hormone in the body. This hormone helps control blood sugar, reduce hunger, slow digestion, and make you feel full for longer. While similar drugs like Ozempic are meant for diabetes, Wegovy is approved for long-term weight loss. It comes in a FlexTouch device, allowing users to adjust their weekly dose easily. Each monthly pack includes four needles. The medicine works on brain areas that manage appetite and food cravings. According to Dr V. Mohan, a well-known diabetologist, 'Semaglutide not only helps in weight loss but also improves heart and inflammation markers. It's a strong option for Indian patients dealing with both obesity and rising heart risks.' Wegovy India Price List Dose Monthly Price (Rs) Price Per Dose (Rs) 0.25 mg Rs 17,345 Rs 4,366 0.5 mg Rs 17,345 Rs 4,366 1 mg Rs 17,345 Rs 4,366 1.75 mg Rs 24,280 Rs 6,070 2.4 mg Rs 26,015 Rs 6,503 For comparison, Eli Lilly's Mounjaro is slightly cheaper: Mounjaro Dose Monthly Price (Rs) 2.5 mg Rs 14,000 5 mg Rs 17,500 Almost like weight loss surgery, but with a catch Wegovy has shown very strong results. In global studies, people lost up to 15% of their weight on average, and some even lost 20%. It also helped lower the risk of heart attacks and strokes and improved liver health. However, the results are mostly maintained only if the person continues using the drug. If stopped, weight gain can return. Doctors also warn that muscle loss may happen over time, so people need to be regularly monitored. Wegovy vs Mounjaro: What's the Difference? Feature Wegovy (Semaglutide) Mounjaro (Tirzepatide) How it works Mimics GLP-1 hormone Acts on GLP-1 and GIP hormones Effect Lowers appetite, slows digestion Improves insulin and reduces appetite Approved for Weight loss Diabetes (off-label for weight loss) How to use Weekly injection via Flexpen Weekly injection via vial Price range Rs 17,345–Rs 26,015 Rs 14,000–Rs 17,500 Inputs from TOI
Time of India
12 hours ago
- Health
- Time of India
Novo Nordisk's Wegovy debuts in India: How it works, who it's for, and how much it costs
Source: iStock In a major development for India's fast-growing anti-obesity drug market, Novo Nordisk on Tuesday officially launched Wegovy, its highly anticipated weight-loss medication, marking a direct challenge to Eli Lilly's already available Mounjaro. Wegovy will be rolled out as a once-weekly injectable, delivered via a FlexTouch pen-like device—a user-friendly, self-administered format that eliminates the need for vials or syringes. The drug is expected to be available in Indian pharmacies by the end of June 2025, according to Vikrant Shrotriya, Managing Director of Novo Nordisk India. A market ripe for disruption Novo Nordisk is betting big on India, where nearly 254 million people live with generalized obesity and 351 million with abdominal obesity. The Danish pharma giant sees India as a key market for future sales, aiming to capture a large share of the country's ₹576 crore anti-obesity drug market, which has quadrupled from ₹133 crore in 2021, according to PharmaTrac. 'Obesity is not just a personal health concern — it is a chronic disease and a national epidemic that India cannot afford to ignore,' said Shrotriya. 'We are bringing Wegovy with the convenience of a world-class, state-of-the-art pen device, and an India-specific price.' by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 5 Books Warren Buffett Wants You to Read In 2025 Blinkist: Warren Buffett's Reading List Undo Source: iStock How Wegovy works: Science behind the shot Wegovy contains semaglutide, a GLP-1 receptor agonist, which mimics a natural hormone responsible for regulating blood sugar, reducing appetite, delaying gastric emptying, and improving satiety. While related drugs like Ozempic are used primarily for type 2 diabetes, Wegovy is specifically approved for chronic weight management in cases of morbid obesity. The FlexTouch device allows patients to dial in their weekly dose, with four needles included in each monthly pack. The drug works on key centers of the brain that regulate hunger and food cravings, promoting weight loss while offering additional metabolic benefits. According to diabetologist Dr. V. Mohan, 'Clinical data on semaglutide demonstrates not just weight loss but also considerable improvement in cardiovascular risk factors and inflammatory markers. For Indians, where diabetes and heart disease are on the rise, access to such evidence-based therapy offers holistic benefits.' India-specific pricing for Wegovy: Full dose list With a pricing strategy tailored for the Indian market, Novo Nordisk is offering the same cost for the initial three dosing strengths: Dose Monthly Price (₹) Per Dose (₹) 0.25 mg ₹17,345 ₹4,366 0.5 mg ₹17,345 ₹4,366 1 mg ₹17,345 ₹4,366 1.75 mg ₹24,280 ₹6,070 2.4 mg ₹26,015 ₹6,503 By comparison, Mounjaro, which contains the dual-action compound tirzepatide, is priced more competitively: Source: iStock Mounjaro Dose Monthly Price (₹) 2.5 mg ₹14,000 5 mg ₹17,500 Results comparable to bariatric surgery — but with caveats Wegovy has demonstrated remarkable outcomes in clinical studies, positioning it as a breakthrough in the treatment of obesity and related conditions. Patients using the drug experienced an average weight loss of nearly 15%, with one in three shedding as much as 20% of their body weight. Beyond weight loss, Wegovy also significantly reduces the risk of major cardiovascular events such as heart attacks and strokes. The drug also had notable benefits for liver health and showed improvement in liver fibrosis. However, the benefits of Wegovy are tied closely to continued use. Discontinuation often results in weight regain, and medical experts have raised concerns about potential muscle mass loss over time, underscoring the need for long-term management and monitoring. Wegovy vs. Mounjaro: Key differences Aspect Wegovy (Semaglutide) Mounjaro (Tirzepatide) Mechanism GLP-1 receptor agonist Dual GIP and GLP-1 receptor agonist Effect Reduces appetite, delays gastric emptying Enhances insulin secretion, appetite suppression Indication Approved for weight loss Approved for diabetes, used off-label for weight loss Dosing Once a week via Flexpen Once a week via single-dose vials Price ₹17,345–₹26,015 per month ₹14,000–₹17,500 per month One step to a healthier you—join Times Health+ Yoga and feel the change
Yahoo
25-04-2025
- Business
- Yahoo
Insulin Delivery Pens Market Size is Estimated to Reach USD 58,086 Mn by 2034
The global insulin delivery pens market size is predicted to increase from USD 25,578 million in 2025 and is anticipated to reach around USD 58,086 million by 2034, expanding at a CAGR of 8.2% from 2025 to 2034. A study published by Statifacts a sister firm of Precedence Research. Ottawa, April 25, 2025 (GLOBE NEWSWIRE) -- According to Statifacts, the global insulin delivery pens market size was exhibited at USD 26,412 million in 2024 and is projected to grow USD 58,086 million by 2034 with a CAGR of 8.2% during the forecast period from 2025 to 2034. The insulin delivery pens market is growing driven by the increasing senior population, technological advancements in insulin delivery devices, the rising prevalence of diabetes, raising awareness about insulin pen use, and the increasing prevalence of diabetes. Request a Sample Databook to Explore our Insights@ Market Overview Insulin delivery pens are injection devices that allow you to deliver preloaded insulin into your subcutaneous tissue, the innermost layer of skin in your body. Taking insulin pens is more convenient due to they combine the syringe and medication in one handy unit. Compared to vials of insulin and syringes, pens come preloaded with insulin, including premixed insulins, and are easy to use. Pens can be a better option if it is difficult to hold vials of insulin. The insulin delivery pens market refers to the production, distribution, and use of insulin delivery pens that contain insulin in a cartridge that is administered into subcutaneous tissue through a fine, replaceable needle. Various studies show that insulin pens have enhanced dosing consistency and accuracy compared with syringes. The use of insulin pens can provide many benefits for hospitalized patients, including reduced costs, enhanced safety, and greater satisfaction among healthcare providers and patients. Advancements in insulin pens help the growth of the market. Smart insulin pens are digital; through the internet, pens automatically share information about the time and amount of insulin received in an injection to an app on our smartphone. The app may have additional functions such as monitoring the insulin expiration date and temperature, sending you alerts if it thinks we may miss an insulin injection, and helping to calculate the insulin amount based on the current blood sugar level. In September 2024, to launch a smart app for insulin FlexTouch pens, Mallya, planned by Novo Nordisk Korea. Mallya is designed to work with FlexTouch pens used for treatments like Fiasp, Ryzodeg, Tresiba, and Xultophy and transmits insulin injection data to a mobile app through Bluetooth. Insulin Delivery Pens Market Key Highlights North America led the market with the biggest market share in 2024 Asia Pacific is predicted to expand the fastest CAGR between 2025 and 2034. By technology, the non-smart injectors segment is estimated to hold the highest market in 2024. By technology, the smart injectors segment is expected to expand at the fastest CAGR over the projected period 2025 to 2034. By product, the disposable insulin pens segment has held the largest market share in 2024. By product, the reusable insulin pens segment is anticipated to grow at the fastest rate in the market from 2025 to 2034. By distribution channel segment accounted the highest market share in 2024. By distribution channel segment is anticipated to grow at the fastest rate in the market from 2025 to 2034. Major Key Trends in Insulin Delivery Pens Market: Adoption of beneficial initiatives: Quality enhancement initiative helps to enhance insulin pen delivery and patient health, and eliminate adverse effects related to insulin pen use. Regular education about safety procedures, with a yearly review for all nurses, will enhance the safety of ongoing insulin pen use in the hospital. Rising diabetes care spending: According to a study, near about 11.6% of participants spent over 30% of their yearly income on diabetes care. Episodes of hospitalization, presence of complications, longer duration of diabetes, lower socioeconomic status, being obese, and older age groups were associated with higher healthcare expenditure. Suitable device insurance policies: According to the Congress government, many Americans have coverage for insulin through a health insurance plan, both through the government program and in the commercial market. Order the Premium Databook Today at the Discounted Rate of $1550! Limitations & Challenges in the Insulin Delivery Pens Market: Strict government regulations: Strict government regulations for insulin delivery pens may lead to limited accessibility, rising costs, and potential delays in advancements. High cost of insulin pumps: Structural factors that can lead to higher insulin costs include limited flexibility for the government to arrange drug prices and the need for transparency in arrangements with pharmacy benefit managers. Presence of alternative insulin delivery devices: Alternatives to insulin delivery pens for type 2 diabetes include exercise, weight loss surgery, injectable medications, oral medications, lifestyle changes, and more. Injection ports, injection pumps, insulin jet injectors, and injection aids are also available for alternative ways to deliver insulin. Development of Insulin Delivery Pens Platforms: Market's Largest Potential Using a smart insulin delivery pen platform, data has the potential to enhance insulin delivery. A smart pen is an insulin pen device that is in touch with a mobile app to track insulin delivery, like the time and dose of insulin given. Smart pen techniques include smart attachments/caps or reusable insulin pens that attach to a prefilled and disposable insulin pen. In November 2022, the launch of a diabetes platform that tracks blood sugar, and insulin pen use announced by Eli Lilly. Regional Analysis:North America held the Dominant Position: Technological Advancement to Support Growth. North America held the largest share of the insulin delivery pens market in 2024. Due to changing lifestyles, the rate of diabetes cases is high in developed countries like the United States and Canada. Major Factors for the Market's Expansion in North America In April 2025, the Omnipod 5 automated insulin delivery system in Canada, a revolutionary new technology for people living with type 1 diabetes aged 2 years and above, was launched by the global leader in tubeless insulin pumps technology, Insulet Corporation. In February 2023, Ypsomed AG, as the manufacturer and supplier of insulin dosing injector pens for the company's affordable insulins, was selected by Civica, Inc. Ned McCoy, president and CEO of Civica, said 'as a renowned injection device specialist with over 35 years' experience, Ypsomed will help Civica make self-administered care for more affordable Americans living with diabetes. What Expect from Asian Countries till 2034? Asia Pacific is projected to host the fastest-growing market in the coming years. Rising demand for advanced insulin injection pens, rising rate of diabetes, and increasing use of digital technologies in insulin delivery systems are driving the growth of the insulin delivery pens market in the Asia Pacific region. Top Asian Countries for Insulin Delivery Pens Treatment India: In March 2023, for the diabetes drug 'Soliqua' (in pre-filled pen), Sanofi (India) received marketing authorization from the CDSCO (Central Drugs Standard Control Organization). Soliqua aims as a treatment to enhance glycemic control as an adjunct to diet and exercise, in elders with obesity and type 2 diabetes who are poorly controlled on injectable or oral therapies. Japan: In January 2024, 510(K) clearance was received from the U.S. Food and Drug Administration (FDA) to market SoloSmart, Sanofi's smart medical device that connects SoloStar insulin pens was announced by a Novo Nordisk company based in France and specialized in the design, development, and manufacturing of innovative medical devices, BIOCORP. Insulin Delivery Pens Market Scope Report Attribute Key Statistics Market Size in 2025 USD 28,578 Million Market Size by 2034 USD 58,086 Million Growth Rate from 2025 to 2034 CAGR of 8.2% Largest Market North America Fastest Growing Market Asia Pacific Base Year 2024 Forecast Period 2025 to 2034 Segments Covered By Product, By Technology, By Distribution Channel, and By Region Regions Covered North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa Technology Insights The non-smart injectors held a dominant presence in the market in 2024. Non-smart injectors are the most cost-effective solution, especially in low-income and emerging economies. They are simple to use and reliable, making them accessible in areas where healthcare access and infrastructure. These factors are contributing to their popularity. The smart injectors segment is projected to experience the highest growth rate in the market between 2025 and 2034. The segment is picking up traction because of the various advantages offered by these smart pens. These smart injectors help track doses automatically, sending reminders to patients, reducing risks of over-dosing or under-dosing. Patients can also use the connected apps and devices to share data with their healthcare providers, allowing for better tracking and improving patient-outcomes. Product Insights The disposable insulin pens segment held a dominant presence in the insulin delivery pens market in 2024. Advanced disposable insulin pen systems provide an alternative to syringes and vials for the administration of insulin. Disposable insulin pens meet criteria for safety, dosing accuracy, and ease of use. The reusable insulin pens segment is expected to grow at the fastest rate in the market during the forecast period of 2025 to 2034. The newer, reusable insulin pens provide a key benefit of correcting a selected dose without losing insulin as compared to traditional methods. We can store unopened pens in the refrigerator. They are good until the expiration date. Many pens are good for 28 days once we open them. In July 2022, to launch the first reusable insulin pen injector 'TouStar', proving that sustainable medicine delivery devices are gaining ground, designed by DCA and manufactured by Sanofi. Distribution Channel Insights The hospital pharmacies segment accounted for a considerable share of the insulin delivery pens market in 2024. The hospital pharmacy's primary mission is the use of medication management in hospitals and other medical centers. Aims of hospital pharmacy include selection, prescription, procurement, delivery, administration, and review of medications to improve patient outcomes. The retail pharmacies segment is projected to experience the highest growth rate in the market between 2025 and 2034. Retail pharmacies are responsible for the correct dispensing of medication for customers to use at home, as well as educating the customers on their medications and answering any questions the customers have. This pharmacy offers services like personalized counseling on medication use, immunizations, and health screenings. Browse More Research Reports: The global non-injectable insulin market size accounted for USD 1,800 million in 2024 and is expected to exceed around USD 6,440 million by 2034, growing at a CAGR of 13.6% from 2024 to 2034. The U.S. medical devices market size is calculated at USD 188.71 billion in 2024 and is predicted to reach around USD 367.77 billion by 2034, expanding at a CAGR of 6.9% from 2024 to 2034. The global wearable medical devices market size accounted for USD 42.71 billion in 2024 and is expected to exceed around USD 430.76 billion by 2034, growing at a CAGR of 26% from 2024 to 2034. The global respiratory device market size is calculated at USD 26,878 million in 2024 and is predicted to reach around USD 69,715 million by 2034, expanding at a CAGR of 10% from 2024 to 2034. The global neurovascular device market size accounted for USD 3,200 million in 2024 and is predicted to touch around USD 4,220 million by 2034, growing at a CAGR of 2.8% from 2024 to 2034. The global single-use pump market size surpassed USD 488 million in 2024 and is predicted to reach around USD 1,701 million by 2034, registering a CAGR of 13.3% from 2025 to 2034. Order the Premium Databook Today at the Discounted Rate of $1550! Insulin Delivery Pens Market Top Companies: Eli Lilly and Company Becton, Dickinson & Company West Pharmaceutical Services, Inc Johnson & Johnson Antares Pharma AbbVie Inc. Pfizer Inc Mylan N.V Vetter Pharma-Fertigung GmbH & Emperra GmbH Digital Medics Pty Ltd Enable Injections LLC Thermo Fisher Scientific Inc. Recent Breakthroughs in the Global Insulin Delivery Pens Market: In March 2025, a probe into insulin pen manufacturers Novo Nordisk and Sanofi Aventis for possible anticompetitive practices was launched by the SA's competition authority. In November 2024, setting the stage for the launch of the Company's Smart MDI system integrated with Simplera continuous glucose monitor (CGM), the US Food and Drug Administration (FDA) has granted clearance to Medtronic's new InPen app, in an advancement for diabetes management. Segments Covered in the Report By Product Reusable Insulin Pens Disposable Insulin Pens Smart Insulin Pens By Technology Non-Smart Injectors Smart Injectors By Distribution Channel Hospital Pharmacies Drug Stores Retail Pharmacies Online Pharmacies By Region North America U.S. Canada Europe U.K. Germany France Asia-Pacific China India Japan South Korea Malaysia Philippines Latin America Brazil Rest of Latin America Middle East & Africa (MEA) GCC North Africa South Africa Rest of the Middle East & Africa You can Place an Order or Ask any Questions, Please Feel Free to Contact us at sales@ Statifacts offers subscription services for data and analytics insights. This page provides options to explore and purchase a subscription tailored to your needs, granting access to valuable statistical resources and tools. Access here - Contact US Ballindamm 22, 20095 Hamburg, Germany Web: Europe: +44 7383 092 044 About US Statifacts is a leading provider of comprehensive market research and analytics services, offering over 1,000,000 market and custoer data sets across various industries. Their platform enables businesses to make informed strategic decisions by providing full access to statistics, downloadable in formats such as XLS, PDF, and PNG. Our Trusted Data Partners: Precedence Research | Towards Healthcare | Towards Packaging | Towards Automotive | Towards Food and Beverages | Towards Chemical and Materials | Towards Dental | Towards EV Solutions | Nova One Advisor
